Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 12,851,000 | 10,027,000 | 2,113,000 | 1,803,694 | 9,883,777 |
| Marketable Securities | 1,756,000 | 101,000 | 19,000 | 58,556 | 16,491 |
| Receivables | 5,854,000 | 4,635,000 | 2,182,000 | 1,751,388 | 1,951,167 |
| Inventories | 1,955,000 | 1,386,000 | 1,697,000 | 1,744,982 | 1,389,983 |
| Income taxes - deferred | 828,000 | 508,000 | 331,000 | 262,641 | 208,155 |
| Other current assets | 0 | 0 | 91,000 | 84,302 | 5 |
| TOTAL | $24,762,000 | $17,714,000 | $6,997,000 | $6,156,347 | $13,918,790 |
| Non-Current Assets | |||||
| PPE Net | 2,276,000 | 1,674,000 | 1,166,000 | 1,100,259 | 774,406 |
| Investments And Advances | 11,601,000 | 1,598,000 | 439,000 | 719,836 | 63,704 |
| Intangibles | 11,419,000 | 12,245,000 | 13,069,000 | 12,797,309 | 2,066,966 |
| Other Non-Current Assets | 1,658,000 | 1,433,000 | 908,000 | 466,086 | 479,273 |
| TOTAL | $26,954,000 | $16,950,000 | $15,582,000 | $15,083,490 | $3,384,349 |
| Total Assets | $51,716,000 | $34,664,000 | $22,579,000 | $21,239,840 | $17,303,130 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 982,000 | 483,000 | 2,697,000 | 1,169,490 | 1,572 |
| Accounts payable and accrued liabilities | 1,178,000 | 955,000 | 1,256,000 | 1,327,339 | 1,206,052 |
| Accrued Expenses | 4,118,000 | 2,316,000 | 1,261,000 | 949,741 | 720,789 |
| TOTAL | $9,890,000 | $5,761,000 | $6,407,000 | $4,237,897 | $2,514,790 |
| Non-Current Liabilities | |||||
| Long Term Debt | 21,468,000 | 12,507,000 | 3,939,000 | 7,304,528 | 7,753,470 |
| Deferred Revenues | 440,000 | 134,000 | 111,000 | 103,162 | 74,665 |
| Other Non-Current Liabilities | 1,247,000 | 619,000 | 423,000 | 140,969 | 150,233 |
| TOTAL | $22,713,000 | $13,084,000 | $4,427,000 | $7,458,219 | $7,920,995 |
| Total Liabilities | $32,603,000 | $18,845,000 | $10,834,000 | $11,696,120 | $10,435,780 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,366,846 | 1,489,402 | 1,538,253 | 1,522,393 | 1,514,631 |
| Common Shares | 1,000 | 2,000 | 2,000 | 1,519 | 753 |
| Retained earnings | 18,001,000 | 12,732,000 | 6,106,000 | 3,704,744 | 1,776,760 |
| Other shareholders' equity | 667,000 | 694,000 | 251,000 | 195,515 | 186,693 |
| TOTAL | $19,113,000 | $15,819,000 | $11,745,000 | $9,543,722 | $6,867,349 |
| Total Liabilities And Equity | $51,716,000 | $34,664,000 | $22,579,000 | $21,239,842 | $17,303,129 |